Amgen Inc. (AMGN) - Stock Analysis

Amgen Inc. Financial Analysis

Current Price: $338.22 +3.03%

Market Cap: $182.54B

Sector: Healthcare

P/E Ratio: 22.84

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-rel

Report Contents

  • Income Statement Analysis (5-year history)
  • Balance Sheet Overview
  • Cash Flow Statement
  • Key Financial Ratios
  • Valuation Metrics (P/E, EV/EBITDA, P/S)
  • Peer Comparison
  • Revenue & Earnings Growth Trends
  • Margin Analysis
  • Analyst Price Targets
  • DCF Valuation Model